A Study of Multiparametric Ultrasound Imaging Methods

Inclusion Criteria40

• Cohort 1 - Feasibility of multiparametric endoscopic ultrasound (mpEUS) imaging of patients at high-risk for pancreatic cancer:
• Patient Group: those having standard endoscopic ultrasounds because they are at high risk of pancreatic cancer Participants enrolled into the Memorial Sloan Kettering Cancer Center Pancreatic Registry protocol (IRB#: 02-102) will be eligible for this study. Specifically, related individuals without pancreatic cancer who are at-risk for developing pancreatic cancer and meet all of the following criteria (family health history will be self-reported):
• years younger than the earliest pancreatic cancer diagnosis in the family
• Be at least 50 years old
• Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A/p16) or Hereditary Pancreatitis (PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)
• Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)
• Not pregnant and not Nursing
• Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)
• Must agree to be contacted for follow-up
• Must satisfy at least one of the following 4 criteria:
• Have at least two affected relatives who are a first-degree relative to each other, of whom at least one is a first degree relative to the individual OR have at least two affected first-degree relatives on the same side of the family.
• Have at least one first- or second-degree affected relative and have germline genetic test results that confirm a likely pathogenic or pathogenic variant in at least one of the following genes:
• APC (Familial Adenomatous Polyposis (FAP) and Attenuated FAP syndrome
• BRCA1(Hereditary Breast and Ovarian Cancer Symptoms)
• MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch Syndrome)
• PALB2
• TP53 (Li-Fraumeni Syndrome)
• Other established pancreatic cancer predisposition gene per project leader's discretion
• Have germline genetic test results that confirm a likely pathogenic or pathogenic variant in one or more of the following genes:
• CDKN2A/p16 (Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM))
• STK11 aka LKB1 (Peutz-Jeghers Syndrome)
• PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes per project leader's discretion
• ATM (ataxia telangiectasia mutated)
• BRCA 2(Hereditary Breast and Ovarian Cancer Symptoms)
• Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined the project leader (Dr. Vineet Rolston)
• Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:
• Patient Group: those with pancreatic cancer having endoscopic ultrasound-guided biopsies
• Patients will be entered into the study if they meet the following criteria:
• Patients with pancreatic ductal adenocarcinoma
• Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care
• Not pregnant and not nursing
• Cohort 3 - Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging:
• Patient Group: those with a thyroid nodule that will be biopsied whether they have known cancer or not
• Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care
• Not pregnant and not nursing
• Healthy Volunteers will be entered into the study if they meet the following criteria:
• No known cancer diagnosis or thyroid nodules
• Age ≥ 18
• Able to understand and give informed consent
• Not pregnant and not nursing